All told, Entresto-treated patients were 46% less likely to die, be re-admitted to hospital with heart failure, need a left ventricular assist device (LVAD), or be put on a waiting list for heart ...

Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind.